Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

436.32 -10.86 (-2.43%)
Streaming Delayed Price Updated: 2:47 PM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Topics Economy Law Enforcement
Exposures Economy Legal Product Safety
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
Via Benzinga
CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?
Via The Motley Fool
Exposures Product Safety
VRTX Q1 Earnings Call: New Product Launches and Pipeline Progress Amid Revenue Miss
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue guidance of... 
Via StockStory
Topics Intellectual Property
Exposures Intellectual Property
Warren Buffett Remains Optimistic About America. Here Are Top American Companies Worth Investing In.
Via The Motley Fool
Topics Economy Government Supply Chain
Exposures Economy Political Supply Chain
1 Large-Cap Stock to Target This Week and 2 to Question
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for... 
Via StockStory
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Best Biotech Stocks to Buy in 2025
Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum. 
Via MarketBeat
Topics ETFs Economy Government
Exposures COVID-19 Interest Rates Political
2 Biotech Stocks That Are Screaming Buys in May
Via The Motley Fool
This Stock Just Dropped by 12% in 1 Day. History Says This Will Happen Next
Via The Motley Fool
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
Exposures Political US Equities
Wynn Resorts, Microsoft, Palantir And A Health Care Stock On CNBC's 'Final Trades'
Via Benzinga
Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years
Via The Motley Fool
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?
The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio? 
Via Benzinga
My Favorite Tariff Safe-Haven Stock to Buy on the Dip
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
4 No-Brainer Stocks to Buy Right Now
Via The Motley Fool
Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Vertex... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Top S&P500 movers in Wednesday's session
Curious about the top performers within the S&P500 index one hour before the close of the markets on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
What's going on in today's session: S&P500 movers
Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip
Via The Motley Fool
Topics Earnings Intellectual Property Law Enforcement
Exposures Financial Intellectual Property Legal
Market Monitor May 7 ( Hims & Hers Health, Upwork UP - Palantir, Monderna DOWN)
Markets slide on vaccine regulation fears, trade uncertainty, and cautious earnings despite strong tech and consumer stock moves. 
Via Chartmill
1 S&P 500 Stock with Impressive Fundamentals and 2 to Ignore
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
Exposures US Equities
Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?
Vertex posted Q1 EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U.S. 
Via Benzinga
What's going on in today's session: S&P500 movers
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Stocks Fall On Trade Concerns, Oil And Gold Rally: What's Driving Markets Tuesday?
Wall Street edged lower by midday Tuesday as uncertainty surrounding trade policies lingered, with investors adopting a cautious approach ahead of Wednesday’s Federal Reserve meeting. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Uncover the latest developments among S&P500 stocks in today's session.
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
Why Vertex Pharmaceuticals Stock Is Sinking Today
Via The Motley Fool
Which S&P500 stocks are gapping on Tuesday?
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Tuesday to find the gap up and gap down stocks in today's session. 
Via Chartmill
Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks
The company paused a study of a cystic fibrosis treatment, right on the heels of a scrapped type 1 diabetes program. 
Via Investor's Business Daily
Topics Government Intellectual Property
Exposures Intellectual Property Political
< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.